Please assess the completion status of the following clinical trial:

Trial Title: MIRACLE Study: A Study of Once-Monthly Intravenous Mircera in Hemodialysis Participants With Chronic Renal Anemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Adults greater than or equal to (≥) 18 years of age~* Chronic renal anemia~* Hemoglobin concentration in country-specific target range (Switzerland: 11 to 13 g/dL; Austria: 10 to 12 g/dL)~* Regular long-term hemodialysis therapy with the same mode of dialysis for ≥3 months~* Continuous intravenous or subcutaneous maintenance ESA treatment during previous 2 months~Exclusion Criteria:~* Transfusion of red blood cells during previous 2 months~* Significant acute or chronic bleeding, such as overt gastrointestinal bleeding~* Active malignant disease (except non-melanoma skin cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Mircera in Renal Anemia (Type: EXPERIMENTAL): Participants will receive intravenous Mircera every 4 weeks for a total of 52 weeks in this single-arm study. The first dose of 120, 200, or 360 mcg will be determined by the dose of ESA received prior to administration of study treatment, while subsequent doses will be adjusted to maintain hemoglobin within a country-specific target range.

Based on this trial design, predict the completion outcome and termination type (if applicable).